

Press Release

ProStrakan Group plc

Update on US Regulatory Status of FORTESTA

Galashiels, UK. 19th October 2009 – ProStrakan Group plc (LSE: PSK), the international specialty pharmaceutical company, today announces that Endo Pharmaceuticals Inc. (NASDAQ: ENDP), its US partner for FORTESTA™ (testosterone) 2% Gel, has received a Complete Response Letter from the US Food and Drug Administration (FDA) for its New Drug Application for this product.

FORTESTA is a patented 2% testosterone transdermal gel, for testosterone replacement therapy in male hypogonadism, which utilises a metered dose delivery system designed to permit accurate dose adjustment to individual patient requirements. This product is currently approved in the EU and marketed in a number of European countries under the brand names: Tostran, Tostrex and Itnogen.

Dr Wilson Totten, Chief Executive of ProStrakan, said:

“We remain confident that we will be able to reassure the FDA that FORTESTA should be approved and our partner, Endo Pharmaceuticals, anticipates filing a complete response to the FDA’s questions in mid-2010. Male hypogonadism remains a problem for many men and our experience in Europe, where this product is already on the market, shows that FORTESTA has a role to play in tackling this condition.”

Ends

Further enquiries:

ProStrakan

Dr Wilson Totten, Chief Executive
Allan Watson, Chief Financial Officer
Callum Spreng, Corporate Comms

Tel: +44 (0) 1896 664000

Brunswick Group

Jon Coles / Justine McIlroy

Tel: +44 (0) 20 7404 5959

Trout Group (for US investor enquiries)

Gitanjali Jain Ogawa

Tel: +1 (646) 378-2949

About Hypogonadism

Male hypogonadism, is frequently characterised by reduced libido, loss of muscle mass, bone density and diminished energy levels. These symptoms can be alleviated through testosterone replacement therapy.

An estimated 13.8 million American men have testosterone levels characterised as below normal (testosterone <300ng/dl). However, only approximately 9% of men with low testosterone are treated with testosterone replacement therapy.

About ProStrakan

ProStrakan Group plc is a rapidly growing specialty pharmaceutical company engaged in the development and commercialisation of prescription medicines for the treatment of unmet therapeutic needs in major markets.

ProStrakan's head office is located in Galashiels in Scotland. The company's development capabilities are centered in Galashiels and Bedminster, New Jersey, USA. Sales and marketing of ProStrakan's portfolio of products are handled by commercial subsidiaries in the UK, US, France, Germany, Spain, Italy and other EU countries.

www.prostrakan.com

About Endo

Endo Pharmaceuticals is a specialty pharmaceutical company engaged in the research, development, sale and marketing of branded and generic prescription pharmaceuticals used to treat and manage pain, overactive bladder, prostate cancer and the early onset of puberty in children, or central precocious puberty (CPP). Its products include LIDODERM[®], a topical patch to relieve the pain of postherpetic neuralgia; Percocet[®] and Percodan[®] tablets for the relief of moderate-to-moderately severe pain; FROVA[®] tablets for the acute treatment of migraine attacks with or without aura in adults; OPANA[®] tablets for the relief of moderate-to-severe acute pain where the use of an opioid is appropriate; OPANA[®] ER tablets for the relief of moderate-to-severe pain in patients requiring continuous, around-the-clock opioid treatment for an extended period of time; Voltaren[®] Gel, which is owned and licensed by Novartis AG, a nonsteroidal anti-inflammatory drug indicated for the relief of the pain of osteoarthritis of joints amenable to topical treatment, such as those of the hands and the knees; VANTAS[®] for the palliative treatment of advanced prostate cancer;

SUPPRELIN® LA for the treatment of early onset puberty in children; and VALSTAR™ for the treatment of BCG-refractory carcinoma in situ (CIS) of the urinary bladder in patients for whom immediate cystectomy would be associated with unacceptable medical risks. The company markets its branded pharmaceutical products to physicians in pain management, urology, endocrinology, oncology, neurology, surgery and primary care. More information, including this and past press releases of Endo Pharmaceuticals, is available at www.endo.com.

1. Araujo AB, O'Donnell AB, Brambilla DJ et al. Prevalence and incidence of androgen deficiency in middle-aged and older men: estimates from the Massachusetts Male Aging Study. *J Clin Endocrinol Metab* 2004; 89(12): 5920–5926.